20 unchanged sentences
The following table summarizes the initial amount of authorized repurchases as well as additional repurchases approved by our Board of Directors as of September 25, 2020 (in thousands):
−Removed: Authorization Period
−Removed: Authorization Amount
+Added: Authorization Period Authorization Amount
November 2009 $ 250,000
+Added: July 2010 300,000
+Added: July 2011 250,000
February 2012 100,000
+Added: October 2014 200,000
+Added: January 2017 200,000
+Added: July 2018 350,000
+Added: July 2019 350,000
+Added: Total $ 2,000,000
The following table provides information regarding our share repurchases made under this program during the fourth quarter of fiscal 2020:
−Removed: Repurchase Activity
−Removed: Total Shares Purchased
−Removed: Average Price
+Added: Repurchase Activity Total Shares Purchased Average Price
Paid Per Share (1)
−Removed: Total Shares Purchased As Part Of Publicly Announced Programs
−Removed: Remaining Authorized Repurchases (2)
−Removed: June 29, 2019 - July 26, 2019
−Removed: $65.0 million
−Removed: July 27, 2019 - August 23, 2019
−Removed: $375.2 million
−Removed: August 24, 2019 - September 27, 2019
−Removed: $360.9 million
+Added: Total Shares Purchased As Part Of Publicly Announced Programs Remaining Authorized Repurchases (2)
+Added: June 27, 2020 - July 24, 2020 — $ — — $232.2 million
+Added: July 25, 2020 - August 21, 2020 491,333 69.92 491,333 $197.8 million
+Added: August 22, 2020 - September 25, 2020 151,363 70.27 151,363 $187.2 million
+Added: Total 642,696 642,696
(1) Average price paid per share excludes commission costs.
15 unchanged sentences
2020 September 27,
−Removed: (as adjusted) (1)
2019 September 28,
−Removed: (as adjusted) (1)
2018 September 29,
2017 September 30,
+Added: Revenue $ 1,161,792 $ 1,241,620 $ 1,054,600 $ 1,080,177 $ 1,025,738
+Added: Gross margin 1,015,294 1,080,766 927,038 961,648 916,756
Operating expenses 796,552 823,689 743,533 714,515 684,961
1 unchanged sentence
Net income attributable to Dolby Laboratories, Inc.
+Added: 231,363 255,151 41,746 206,481 185,860
Net Income Per Share:
+Added: Basic $ 2.30 $ 2.51 $ 0.40 $ 2.03 $ 1.85
+Added: Diluted $ 2.25 $ 2.44 $ 0.39 $ 2.00 $ 1.81
Weighted-Average Shares Outstanding:
+Added: Basic 100,564 101,629 103,377 101,784 100,717
+Added: Diluted 102,944 104,572 106,978 103,286 102,424
Cash dividends declared per common share $ 0.88 $ 0.79 $ 0.67 $ 0.58 $ 0.50
3 unchanged sentences
2020 September 27,
−Removed: (as adjusted) (1)
2019 September 28,
−Removed: (as adjusted) (1)
2018 September 29,
3 unchanged sentences
Short-term and long-term investments 99,097 298,733 365,920 562,121 515,533
+Added: Total assets 2,917,325 2,821,749 2,865,387 2,836,463 2,310,106
Total stockholders’ equity—Dolby Laboratories, Inc.
−Removed: The selected financial data for the fiscal years ended September 28, 2018 and September 29, 2017 have been adjusted to reflect the adoption of ASU 2014-09, Revenue from Contracts with Customers, or "ASC 606".
−Removed: The selected financial data for fiscal years ended September 30, 2016 and September 25, 2015 presented in the table above reflects ASC 605, and has not been recast for, and does not reflect the adoption of ASC 606.
−Removed: For additional information, refer to Note 2 " Summary Of Significant Accounting Policies " to our consolidated financial statements.
+Added: 2,432,643 2,307,351 2,363,936 2,391,627 1,970,256
+Added: (1) The selected financial data for fiscal year ended September 30, 2016 presented in the table above reflects ASC 605, and has not been recast for, and does not reflect the adoption of ASC 606.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.